Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection.
Natural killer (NK) cells have been reported to be dysfunctional in chronic hepatitis B (CHB) infection. However, the functional recovery of NK cells under antiviral therapeutic agents in CHB was not clearly understood. In this study, we investigated the phenotypic changes of NK(CD56+CD3-) cells in terms of their functional markers (CD16, NKG2A, NKG2D) during tenofovir therapy in CHB. The frequency of NK(CD56+CD3-) cells in CHB patients was significantly increased after 12 months of tenofovir therapy when compared with baseline. The expression levels of CD16+/CD56+CD3- and NKG2A+/CD56+CD3- cells were also affected by tenofovir treatment. In addition, there was a positive correlation between the proportion of NK(CD56+CD3-) cells and HBV DNA (log copies/ml) in CHB patients.
Department of Pharmacy, College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea.|Innovative Drug Center, Duksung Women's University, Seoul 01369, Republic of Korea.
Hwan Hee
HH
Lee
College of Pharmacy, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University, Daegu 41566, Republic of Korea.
Hyojeung
H
Kang
Department of Pharmacy, College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea.|Innovative Drug Center, Duksung Women's University, Seoul 01369, Republic of Korea.
Hyosun
H
Cho
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D002452:Cell Count; D004279:DNA, Viral / Q000097:blood; D005260:Female; D058851:GPI-Linked Proteins / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D055654:NK Cell Lectin-Like Receptor Subfamily C / Q000276:immunology; D017452:Receptors, IgG / Q000276:immunology; D000068698:Tenofovir / Q000627:therapeutic use*; D013997:Time Factors
D000998:Antiviral Agents; D017252:CD3 Complex; D019002:CD56 Antigen; D004279:DNA, Viral; C428200:FCGR3B protein, human; D058851:GPI-Linked Proteins; C522918:NCAM1 protein, human; D055654:NK Cell Lectin-Like Receptor Subfamily C; D017452:Receptors, IgG; D000068698:Tenofovir
CD16; Chronic hepatitis B; NKG2A; natural killer (NK) cells; tenofovir